Study Summary
This is a single-arm, open-label, single-center, phase I study. The primary objective is to evaluate the safety of CD7 CAR-T therapy for patients with CD7-positive relapsed or refractory T-ALL/LBL/AML, and to evaluate the pharmacokinetics of CD7 CAR-T in patients.
Want to learn more about this trial?
Request More InfoInterventions
RD13-02 cell infusionDRUG
CAR-T cells
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Affiliated hospital of Xuzhou medical college | Xuzhou | Jiangsu | China |